Cargando…

Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer

BACKGROUND: m(6)A modification affects the pathological progress of many diseases by affecting RNA stability and translocation. YTHDC2, a m(6)A reader, is associated with multiple cancers; however, little is known of its role in non‐small cell lung cancer (NSCLC). METHODS: The GEPIA, Oncomine and GE...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shulei, Han, Qiang, Liang, Maoli, Zhang, Qian, Zhang, Jing, Cao, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606000/
https://www.ncbi.nlm.nih.gov/pubmed/32956555
http://dx.doi.org/10.1111/1759-7714.13667
_version_ 1783604422765445120
author Sun, Shulei
Han, Qiang
Liang, Maoli
Zhang, Qian
Zhang, Jing
Cao, Jie
author_facet Sun, Shulei
Han, Qiang
Liang, Maoli
Zhang, Qian
Zhang, Jing
Cao, Jie
author_sort Sun, Shulei
collection PubMed
description BACKGROUND: m(6)A modification affects the pathological progress of many diseases by affecting RNA stability and translocation. YTHDC2, a m(6)A reader, is associated with multiple cancers; however, little is known of its role in non‐small cell lung cancer (NSCLC). METHODS: The GEPIA, Oncomine and GEO databases were analyzed to assess expression of YTHDC2 in NSCLC patients. Quantitative polymerase chain reaction, western blot and immunohistochemistry were used to detect YTHDC2 expression in different NSCLC cell lines (H1299, H460, H292 and A549) and patients. The effects of YTHDC2 on NSCLC cell lines (A549 and H1299) proliferation and migration were employed using CCK8 and transwell assays. The potential target RNAs of YTHDC2 were obtained from the POSTAR database. Functional enrichment analysis of YTHDC2 targeted RNAs was performed using the Metascape database. RESULTS: GEPIA, Oncomine and GEO databases showed low expression of YTHDC2 in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. YTHDC2 expression was significantly decreased in different NSCLC cell lines and our clinical samples. Moreover, low expression of YTHDC2 was significantly associated with poor differentiation, lymph node metastasis, tumor size and stage. In addition, YTHDC2 could suppress the proliferation and migration ability of A549 and H1299 cell lines. Kaplan‐Meier Plotter database analysis revealed that patients with low level of YTHDC2 had a significantly poor prognosis. Finally, functional enrichment analysis of YTHDC2 targeted RNAs indicated several enriched pathways related to cancer. CONCLUSIONS: These findings elucidate that YTHDC2 suppresses tumorigenesis in NSCLC, indicating that YTHDC2 may be a promising therapeutic target for NSCLC. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: This study demonstrated that the downregulation of YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer (NSCLC). WHAT THIS STUDY ADDS: YTHDC2 might be a promising therapeutic target for non‐small cell lung cancer (NSCLC).
format Online
Article
Text
id pubmed-7606000
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-76060002020-11-05 Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer Sun, Shulei Han, Qiang Liang, Maoli Zhang, Qian Zhang, Jing Cao, Jie Thorac Cancer Original Articles BACKGROUND: m(6)A modification affects the pathological progress of many diseases by affecting RNA stability and translocation. YTHDC2, a m(6)A reader, is associated with multiple cancers; however, little is known of its role in non‐small cell lung cancer (NSCLC). METHODS: The GEPIA, Oncomine and GEO databases were analyzed to assess expression of YTHDC2 in NSCLC patients. Quantitative polymerase chain reaction, western blot and immunohistochemistry were used to detect YTHDC2 expression in different NSCLC cell lines (H1299, H460, H292 and A549) and patients. The effects of YTHDC2 on NSCLC cell lines (A549 and H1299) proliferation and migration were employed using CCK8 and transwell assays. The potential target RNAs of YTHDC2 were obtained from the POSTAR database. Functional enrichment analysis of YTHDC2 targeted RNAs was performed using the Metascape database. RESULTS: GEPIA, Oncomine and GEO databases showed low expression of YTHDC2 in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. YTHDC2 expression was significantly decreased in different NSCLC cell lines and our clinical samples. Moreover, low expression of YTHDC2 was significantly associated with poor differentiation, lymph node metastasis, tumor size and stage. In addition, YTHDC2 could suppress the proliferation and migration ability of A549 and H1299 cell lines. Kaplan‐Meier Plotter database analysis revealed that patients with low level of YTHDC2 had a significantly poor prognosis. Finally, functional enrichment analysis of YTHDC2 targeted RNAs indicated several enriched pathways related to cancer. CONCLUSIONS: These findings elucidate that YTHDC2 suppresses tumorigenesis in NSCLC, indicating that YTHDC2 may be a promising therapeutic target for NSCLC. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: This study demonstrated that the downregulation of YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer (NSCLC). WHAT THIS STUDY ADDS: YTHDC2 might be a promising therapeutic target for non‐small cell lung cancer (NSCLC). John Wiley & Sons Australia, Ltd 2020-09-21 2020-11 /pmc/articles/PMC7606000/ /pubmed/32956555 http://dx.doi.org/10.1111/1759-7714.13667 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Sun, Shulei
Han, Qiang
Liang, Maoli
Zhang, Qian
Zhang, Jing
Cao, Jie
Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer
title Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer
title_full Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer
title_fullStr Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer
title_full_unstemmed Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer
title_short Downregulation of m(6)A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer
title_sort downregulation of m(6)a reader ythdc2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606000/
https://www.ncbi.nlm.nih.gov/pubmed/32956555
http://dx.doi.org/10.1111/1759-7714.13667
work_keys_str_mv AT sunshulei downregulationofm6areaderythdc2promotestumorprogressionandpredictspoorprognosisinnonsmallcelllungcancer
AT hanqiang downregulationofm6areaderythdc2promotestumorprogressionandpredictspoorprognosisinnonsmallcelllungcancer
AT liangmaoli downregulationofm6areaderythdc2promotestumorprogressionandpredictspoorprognosisinnonsmallcelllungcancer
AT zhangqian downregulationofm6areaderythdc2promotestumorprogressionandpredictspoorprognosisinnonsmallcelllungcancer
AT zhangjing downregulationofm6areaderythdc2promotestumorprogressionandpredictspoorprognosisinnonsmallcelllungcancer
AT caojie downregulationofm6areaderythdc2promotestumorprogressionandpredictspoorprognosisinnonsmallcelllungcancer